Send to

Choose Destination
Radiol Oncol. 2014 Jan 22;48(1):20-8. doi: 10.2478/raon-2013-0049. eCollection 2014 Mar.

Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey.

Author information

Department for nuclear medicine, University Medical Centre, Ljubljana, Slovenia.
Médecine nucléaire, Hôpital Tenon, AP-HP, Paris, France ; Université Pierre et Marie Curie, Paris, France.
Médecine nucléaire, Hôpital Tenon, AP-HP, Paris, France.
Médecine nucléaire, Hôpital Tenon, AP-HP, Paris, France ; Comenius University, Bratislava, Slovakia.
Radiopharmacie, Hôpital Tenon, AP-HP, Paris, France.
Nuklearmedizin, Kassel Klinikum, Kassel, Germany.



Fluorocholine(18F) (FCH) was introduced at the beginning of April 2010 in France, Slovenia and three other EU member states for the localisation of bone metastases of prostate cancer with PET. The aim of the study was to compare the evolution of diagnostic imaging in patients with prostate cancer using a new radiopharmaceutical FCH, observed in France and in Slovenia, and to quantify the consequence of the results of new imaging modality on the detection rate of abnormal metastases and recurrences of prostate cancer.


In two centres (France/Slovenia), a survey of the number of nuclear medicine examinations in patients with prostate cancer was performed, covering 5 quarters of the year since the introduction of FCH. For each examination, the clinical and biological circumstances were recorded, as well as the detection of bone or soft tissue foci.


Six hundred and eighty-eight nuclear medicine examinations were performed impatients with prostate cancer. Nuclear medicine examinations were performed for therapy monitoring and follow-up in 23% of cases. The number of FCH PET/CT grew rapidly between the 1(st) and 5(th) period of the observation (+220%), while the number of bone scintigraphies (BS) and fluoride(18F) PET/CTs decreased (-42% and -23% respectively). Fluorodeoxyglucose(18F) (FDG) PET/CT remained limited to few cases of castrate-resistant or metastatic prostate cancer in Paris. The proportion of negative results was significantly lower with FCH PET/CT (14%) than with BS (49%) or fluoride(18F) PET/CT (54%). For bone metastases, the detection rate was similar, but FCH PET/CT was performed on average at lower prostate-specific antigen (PSA) levels and was less frequently doubtful (4% vs. 28% for BS). FCH PET/CT also showed foci in prostatic bed (53% of cases) or in soft tissue (35% of cases).


A rapid development of FCH PET/CT was observed in both centres and led to a higher detection rate of prostate cancer lesions.


PET/CT; bone scintigraphy; fluoride(18F); fluorocholine (FCH); indication of imaging; prostate cancer

Supplemental Content

Full text links

Icon for Sheridan PubFactory Icon for PubMed Central
Loading ...
Support Center